Drug Information

General Information
Drug ID
DR00291
Drug Name
Cisplatin
Synonyms
(SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Abiplatin; Biocisplatinum; Briplatin; Cis-DDP; Cis-Diamminedichloroplatinum; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Cismaplat; Cisplatin (Chemotherapy); Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Peyrone's chloride; Peyrone's salt; Plastin; Platamine; Platidiam; Platinoxan; Randa; Trans-diamminedichloridoplatinum(II)
Drug Type
Small molecular drug
Indication Ovarian cancer [ICD11:2C73] Approved [1]
Sarcomas [ICD11:2C35] Approved [1]
Testicular cancer [ICD11:2C80] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
Cl2H6N2Pt+2
Canonical SMILES
N.N.Cl[Pt+2]Cl
InChI
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+4/p-2
InChIKey
BSJGASKRWFKGMV-UHFFFAOYSA-L
CAS Number
CAS 15663-27-1
Pharmaceutical Properties Molecular Weight 300.05 Topological Polar Surface Area 2
Heavy Atom Count 5 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 2
PubChem CID
441203
PubChem SID
134337530 ,137007875 ,137521154 ,139486572 ,14718343 ,160844883 ,160844890 ,17405476 ,175444044 ,175444045 ,249871544 ,252401149 ,36885096 ,57393766 ,74440810 ,7783791 ,8139843 ,8144441
ChEBI ID
ChEBI:27899
TTD Drug ID
D0U5HU
DT(s) Transporting This Drug 1-Oct Transporter Info Organic cation transporter 1 Substrate [2]
2-Oct Transporter Info Organic cation transporter 2 Substrate [3]
ABCG1 Transporter Info ATP-binding cassette sub-family G member 1 Substrate [4]
ATP7B Transporter Info Copper-transporting ATPase 2 Substrate [5]
BCRP Transporter Info Breast cancer resistance protein Substrate [6]
COPT2 Transporter Info Probable low affinity copper uptake protein 2 Substrate [7]
CTR1 Transporter Info High affinity copper uptake protein 1 Substrate [8]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [9]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [10]
MRP6 Transporter Info Multidrug resistance-associated protein 6 Substrate [11]
P-GP Transporter Info P-glycoprotein 1 Substrate [12]
References
1 Cisplatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
3 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
4 The role of ATP-binding cassette subfamily G member 1 in tumor progression. Cancer Med. 2024 Jun;13(12):e7285.
5 Effect of cisplatin on the transport activity of PII-type ATPases. Metallomics. 2017 Jul 19;9(7):960-968.
6 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
7 Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2011 Jan;79(1):157-66.
8 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
9 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
10 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
11 Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
12 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.